Log inBook a demo
PlatformPlatform overviewCOA reviewSupplier qualificationSupplier follow-up (Vera)Mock inspections (Cato)Patient traceabilityRelease workflowsChain of custodySupplier document collectionAPIPricing
SolutionsCompounding pharmacies503B outsourcing facilitiesClinicsMed spasTelehealth platformsConsultantsSolutions overview
ResourcesMethodologyOrder-level COA traceabilitySupplier packet diligenceResource libraryPublic toolsIntelligenceTrust Center
CompanyAbout VerituraWhy independentPartnersFor counselContact
Log inBook a demo

BPC-157 acetate: BPC-157 acetate. What its COA has to show.

BPC-157 in HHS's peptide policy: its identity, the dosage forms covered, and the tests its certificate of analysis reports. Last reviewed November 11, 2026.

BPC-157 acetateAs Appendix B prints it

Amino acid sequence

Molecular formula
C62H98N16O22·xCH3COOH
Molecular weight
1419.54 + x(60.05) g/mol
Amino acids
15

Dosage forms Appendix B covers

SubcutaneousIntramuscularOralTopicalIntranasal (not covered)

One of six. See all six.

What a BPC-157 acetate COA has to show under HHS's peptide policy.

BPC-157 is one of the six peptides in Appendix A of HHS's peptide policy. Appendix B prints its identity, covers it for set dosage forms, and sets the tests its certificate of analysis reports.

This page sets those lines out so a COA can be read against them. The ten conditions are on the policy page.

Reviewed November 11, 2026. Quotations are the source's own words: the policy's, or the Federal Register notice's where the page says so. Where this page gives our practice, it says so; that part is Veritura's reading, not a rule of HHS, the FDA or a board.

What sets BPC-157 apart

Three things on its lines in Appendix B that the other five do not share.

Four dosage forms. BPC-157 is the only one of the six that Appendix B covers in four dosage forms: subcutaneous, intramuscular, oral and topical. That makes the intended dosage form on its COA count for more here than anywhere else, because note 4 ties bioburden and endotoxins to the injectable forms.

An open count of acetate. Appendix B prints the formula as C62H98N16O22·xCH3COOH and the weight as 1419.54 + x(60.05) g/mol. The x is the number of acetates, which it leaves open. The counter-ion row of the testing table is where a COA reports the acetate it found.

Fifteen amino acids. That is over the policy's line for complex peptides, 8 amino acids or more, so its COA also reports higher order structure, aggregates and biological activity.

Identity, as Appendix B prints it

Condition 2 asks for "the identity and limitations in route of administration described in Appendix B." "The identity includes but is not limited to amino acid sequence, chemical structure, molecular weight, and molecular formula."

Appendix B prints the sequence as H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH, 15 amino acids, the formula as C62H98N16O22·xCH3COOH and the weight as 1419.54 + x(60.05) g/mol. The card at the top of this page sets them out.

The form. Appendix B prints BPC-157 as the acetate, C62H98N16O22·xCH3COOH, 1419.54 + x(60.05) g/mol. A COA that gives the formula without the acetate, or the free peptide's weight, does not match those lines. In our reading that is a discrepancy to settle with the supplier before the lot is used.

Its history. Appendix B gives it in one sentence: "BPC-157 (free base) and BPC-157 acetate were in Category 2 from September 2023 until April 22, 2026, and neither the placement nor the removal changed their status under section 503A; Center for Drug Evaluation and Research (CDER) recommended against listing either form, and the Pharmacy Compounding Advisory Committee (PCAC) voted in favor of inclusion."

The dosage forms it covers

Appendix B covers BPC-157 acetate for "subcutaneous, intramuscular, oral, and topical dosage forms".

Injectable forms. Condition 9: the only drug delivery device co-packaged with or containing the preparation is "an FDA 510(k)-cleared syringe." Note 4 names bioburden and bacterial endotoxins as "Critical Quality Attributes (CQAs) specific to injectable dosage forms".

Oral forms. Condition 8: "Achieving adequate oral bioavailability of peptides is inherently difficult and complex." For an oral form, "the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans."

Topical forms. Note 4: "If the BDS is intended for incorporation into an alternative dosage form, the appropriate quality tests specific to that dosage form should be conducted and the results reported on the COA."

One active ingredient. Condition 7: "The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A." In our reading, that rules out a blend of BPC-157 with another peptide or another active ingredient.

Other forms. Appendix B lists no intranasal form for BPC-157.

The tests its COA reports

The test names are the policy's. Whether each one applies to BPC-157 acetate is our reading of the table's own qualifiers. The full table, with methods and references, is on the Appendix B page.

16 apply3 depend on the lot1 do not apply

Listed for every peptide12

  • Physicochemical propertiesApplies. By orthogonal methods from the policy's Table 1.
  • Identification / primary sequenceApplies. By at least two independent methods (note 3), "verified to be the BDS listed in this guidance".
  • AssayApplies. HPLC or RP-HPLC against a quantitative reference standard.
  • ImmunoassayApplies. Listed for every peptide, with no qualifier.
  • Peptide content (net)Applies. Amino acid analysis, nitrogen, UV or qNMR.
  • Peptide-related impuritiesApplies. Specified, unspecified and total, against ICH Q3A.
  • Residual solventsApplies. Gas chromatography, against USP <467>.
  • Elemental impuritiesApplies. ICP-MS, against USP <232> and <233>.
  • Residual TFAApplies. Ion chromatography.
  • Residual fluorideApplies. Ion-selective electrodes.
  • Water contentApplies. Karl Fischer titration.
  • Nitrosamine impuritiesApplies. Small-molecule nitrosamines are listed with no qualifier; NDSRIs "when applicable (in the presence of secondary, tertiary, or quaternary amines)".

Tied to injectable forms2

  • BioburdenDepends. For a lot meant for an injectable form. For an oral or topical lot, note 4 asks for the tests specific to that form.
  • Bacterial endotoxinsDepends. For a lot meant for an injectable form. For an oral or topical lot, note 4 asks for the tests specific to that form.

Depends on the peptide6

  • Counter-ion contentApplies. BPC-157 is the acetate, and the table asks for acetate content.
  • Higher order structureApplies. BPC-157 has 15 amino acids; the table sets this for complex peptides of 8 or more.
  • AggregatesApplies. BPC-157 has 15 amino acids; the table sets this for complex peptides of 8 or more.
  • Biological activity / bioassaysApplies. BPC-157 has 15 amino acids; the table sets this for complex peptides of 8 or more.
  • Host cell-related impuritiesDepends. Only for a recombinant product. The supplier can say how the lot was made.
  • Thiol groupsDoes not apply. Required only if cysteine is present, and BPC-157's sequence has none.

Each result carries its method number and the number of its validation or verification report (note 2).

Where we look twice

Our practice when a BPC-157 COA comes in. It follows from the lines above; it is not a rule of HHS or the FDA.

  1. The form

    The formula and weight are the acetate's, as Appendix B prints them.

  2. The dosage form

    Note 1 asks the COA for "a statement of purpose (i.e., intended dosage form, such as injectable, oral, etc.)". For BPC-157 it is one of the forms above.

  3. The maker

    Note 1 asks for the "Manufacturer's corporate name, its FDA Establishment Identification (FEI) number, address". Condition 4 puts the plant's physical location on the COA.

  4. Larger-peptide tests

    Higher order structure, aggregates and biological activity, because BPC-157 has 15 amino acids.

  5. The methods

    Each result has a method number and a report number beside it, and identification rests on two methods.

Where the policy stands

As of November 11, 2026.

HHS announced the policy in the Federal Register on October 30, 2026, in FR Doc. 2026-22192. The notice says "HHS is announcing the availability of a draft" policy, and that "Written comments can be submitted until 2 weeks after date of publication in the Federal Register via regulations.gov on Docket No. HHS-OASH-2026-0496". It also says the policy "does not establish any rights for any person and is not binding on HHS or the public."

The policy calls itself an interim policy, and says: "HHS may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises with a compounded drug product within the scope of this policy."

It does not put the six peptides on the 503A bulks list. The notice says the FDA's future rulemakings "may propose adding some or all of these peptides to the 503A bulks list based on the available evidence." For the current text, the notice points to the HHS website "to find the most current version of the policy."

Sources

Every source below was opened and read for this page. Last reviewed: November 11, 2026.

We read documents. We do not test material.